Danaher Corporation $DHR Shares Acquired by Soltis Investment Advisors LLC

Soltis Investment Advisors LLC increased its holdings in shares of Danaher Corporation (NYSE:DHR) by 15.3% in the second quarter, Holdings Channel reports. The firm owned 1,981 shares of the conglomerate’s stock after buying an additional 263 shares during the quarter. Soltis Investment Advisors LLC’s holdings in Danaher were worth $391,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Vanguard Group Inc. raised its holdings in shares of Danaher by 0.4% in the first quarter. Vanguard Group Inc. now owns 59,981,088 shares of the conglomerate’s stock valued at $12,296,123,000 after buying an additional 230,966 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in Danaher by 3.2% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 19,592,211 shares of the conglomerate’s stock valued at $4,016,404,000 after acquiring an additional 612,154 shares during the period. Invesco Ltd. raised its stake in Danaher by 44.5% during the 1st quarter. Invesco Ltd. now owns 4,708,578 shares of the conglomerate’s stock valued at $965,259,000 after acquiring an additional 1,450,703 shares during the last quarter. Charles Schwab Investment Management Inc. raised its stake in Danaher by 4.0% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 4,230,087 shares of the conglomerate’s stock valued at $867,168,000 after acquiring an additional 163,332 shares during the last quarter. Finally, Nuveen LLC acquired a new stake in Danaher during the 1st quarter worth approximately $833,941,000. 79.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In related news, Director Teri List sold 2,778 shares of Danaher stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares of the company’s stock, valued at approximately $4,379,706.06. The trade was a 11.81% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 11.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on DHR. UBS Group dropped their target price on Danaher from $240.00 to $225.00 and set a “buy” rating on the stock in a report on Wednesday, July 23rd. TD Cowen boosted their price objective on shares of Danaher from $250.00 to $260.00 and gave the company a “buy” rating in a research note on Wednesday, October 22nd. Barclays upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Wells Fargo & Company restated a “positive” rating on shares of Danaher in a research note on Thursday, October 23rd. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a research note on Sunday, November 2nd. Eighteen research analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Danaher Stock Performance

Shares of DHR opened at $209.89 on Friday. The company has a quick ratio of 1.10, a current ratio of 1.52 and a debt-to-equity ratio of 0.33. Danaher Corporation has a 52-week low of $171.00 and a 52-week high of $258.23. The company has a 50-day simple moving average of $204.02 and a 200-day simple moving average of $200.32. The company has a market capitalization of $148.26 billion, a PE ratio of 43.28, a P/E/G ratio of 3.28 and a beta of 0.81.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, October 21st. The conglomerate reported $1.89 EPS for the quarter, topping analysts’ consensus estimates of $1.72 by $0.17. Danaher had a net margin of 14.44% and a return on equity of 10.92%. The firm had revenue of $6.05 billion for the quarter, compared to the consensus estimate of $6 billion. During the same quarter in the previous year, the firm earned $1.71 earnings per share. The firm’s revenue was up 4.4% on a year-over-year basis. Danaher has set its FY 2025 guidance at 7.700-7.800 EPS. Equities research analysts predict that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, October 31st. Investors of record on Friday, September 26th were issued a $0.32 dividend. The ex-dividend date was Friday, September 26th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. Danaher’s dividend payout ratio is currently 26.39%.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.